Postoperative Chemotherapy After Surgical Resection of Metachronous Metastases of Colorectal Cancer: A Systematic Review

Sevindzh Evdokimova; Anna Kornietskaya; Larisa Bolotina; Dmitriy Sidorov; Andrey Kaprin

doi:10.14740/wjon1568

Postoperative Chemotherapy After Surgical Resection of Metachronous Metastases of Colorectal Cancer: A Systematic Review

World J Oncol. 2023 Feb;14(1):26-31. doi: 10.14740/wjon1568. Epub 2023 Feb 26.

Authors

Sevindzh Evdokimova¹, Anna Kornietskaya², Larisa Bolotina², Dmitriy Sidorov³, Andrey Kaprin^{1

4}

Affiliations

¹ P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow125284, Russia.
² Department of Chemotherapy, P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
³ Abdominal Oncology, City Clinical Oncological Hospital No. 1, Moscow 105005, Russia.
⁴ Urology Department, Peoples' Friendship University of Russia, Moscow117198, Russia.

Abstract

Currently, 6 months of perioperative or adjuvant chemotherapy (ACT) is a standard treatment option after radical surgical removal of metachronous metastases in patients with metastatic colorectal cancer (CRC). Data show that ACT improves relapse-free survival in such patients, although no difference in overall survival rate was observed. We perform a systematic review to evaluate the efficacy of adjuvant chemotherapy after radical resection of metachronous metastases in CRC.

Keywords: Adjuvant chemotherapy; Colorectal cancer; Liver metastases; Metachronous metastases; Radical resection.

Publication types

Review